TRUS biopsy: previous antibiotic exposure is linked to infection risk

  • Danielsen L & al.
  • Scand J Urol
  • 9 May 2019

  • International Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Patients previously treated with antibiotics for UTIs are more likely to develop serious infections after transrectal ultrasound (TRUS)-guided prostate biopsy.

Why this matters

  • Infection is the most dangerous adverse event after TRUS biopsy, and anticipating and minimizing this risk is important.

Study design

  • Researchers studied patients who underwent TRUS biopsy (N=590; median age, 69 years; age range, 39-91 years).
  • Funding: None disclosed.

Key results

  • 530 patients (89.8%) received standard prophylaxis of ciprofloxacin monotherapy before TRUS biopsy.
  • 74 (12.5%) had previously received intravenous broad-spectrum antibiotics.
  • 261 (44.2%) had previously received other antibiotics.
  • 37 (6.1%) were hospitalized after biopsy with symptoms of infection.
  • Patients previously exposed to narrow-spectrum oral antibiotics were most likely to be hospitalized after biopsy (OR, 2.56; 95% CI, 1.27-5.42; P=.01).

Limitations

  • The study was retrospective and conducted at a single center in Denmark; results may not apply to other populations.
  • Researchers may have underestimated antibiotic exposures because of handwritten prescriptions.